Adial Pharmaceuticals, Inc. Operating Cash Flow
Adial Pharmaceuticals, Inc. (ADIL) reported Operating Cash Flow of -$7.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.36M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.61M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.32M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.83M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$6.49M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$6.92M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$6.81M.
- Adial Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$11.19M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$7.97M 10-Q · filed 2026-08-14 | -$9.30M derived: sum of 3 quarters · filed 2026-08-14 | -$11.13M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$1.61M 10-Q · filed 2026-05-08 | -$2.94M derived: sum of 2 quarters · filed 2026-05-08 | -$4.77M derived: sum of 3 quarters · filed 2026-05-08 | -$6.52M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$3.16M derived: sum of 2 quarters · filed 2026-03-05 | -$4.91M derived: sum of 3 quarters · filed 2026-08-14 | -$6.49M 10-K · filed 2026-03-05 | |
| 2025-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.58M derived: sum of 2 quarters · filed 2026-08-14 | -$5.17M 10-Q · filed 2025-11-13 | -$6.62M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$3.33M 10-Q · filed 2026-08-14 | -$3.33M 10-Q · filed 2025-08-13 | -$4.79M derived: sum of 3 quarters · filed 2026-08-14 | -$6.48M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$1.59M 10-Q · filed 2026-05-08 | -$3.04M derived: sum of 2 quarters · filed 2026-05-08 | -$4.73M derived: sum of 3 quarters · filed 2026-05-08 | -$6.88M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$3.15M derived: sum of 2 quarters · filed 2026-03-05 | -$5.30M derived: sum of 3 quarters · filed 2026-03-05 | -$6.92M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.84M derived: sum of 2 quarters · filed 2025-11-13 | -$5.47M 10-Q · filed 2025-11-13 | -$6.69M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$3.77M 10-Q · filed 2025-08-13 | -$5.00M derived: sum of 3 quarters · filed 2025-08-13 | -$6.39M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$1.63M 10-Q · filed 2025-05-14 | -$2.85M derived: sum of 2 quarters · filed 2025-05-14 | -$4.24M derived: sum of 3 quarters · filed 2025-05-14 | -$6.13M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$2.61M derived: sum of 2 quarters · filed 2025-03-04 | -$4.51M derived: sum of 3 quarters · filed 2025-03-04 | -$6.81M 10-K · filed 2025-03-04 | |
| 2023-09-30 | -$1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$3.29M derived: sum of 2 quarters · filed 2024-11-13 | -$5.58M 10-Q · filed 2024-11-13 | -$7.34M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$4.19M 10-Q · filed 2024-08-13 | -$5.94M derived: sum of 3 quarters · filed 2024-08-13 | -$9.35M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$2.30M 10-Q · filed 2023-05-12 | -$4.05M derived: sum of 2 quarters · filed 2024-04-01 | -$7.45M derived: sum of 3 quarters · filed 2024-04-01 | -$10.99M derived: sum of 4 quarters · filed 2024-04-01 | |
| 2022-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$5.15M derived: sum of 2 quarters · filed 2024-04-01 | -$8.69M derived: sum of 3 quarters · filed 2024-04-01 | -$11.19M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$3.40M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | -$6.94M derived: sum of 2 quarters · filed 2023-11-14 | -$9.44M 10-Q · filed 2023-11-14 | -$11.81M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$3.53M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | -$6.03M 10-Q/A · filed 2023-10-30 | -$8.40M derived: sum of 3 quarters · filed 2023-10-30 | -$11.93M derived: sum of 4 quarters · filed 2023-10-30 | |
| 2022-03-31 | -$2.50M 10-Q · filed 2023-05-12 | -$4.87M derived: sum of 2 quarters · filed 2023-05-12 | -$8.40M derived: sum of 3 quarters · filed 2023-05-12 | -$11.60M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$5.90M derived: sum of 2 quarters · filed 2023-03-30 | -$9.11M derived: sum of 3 quarters · filed 2023-03-30 | -$11.95M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$6.73M derived: sum of 2 quarters · filed 2022-11-14 | -$9.58M 10-Q · filed 2022-11-14 | -$12.19M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$6.05M 10-Q · filed 2022-08-15 | -$8.66M derived: sum of 3 quarters · filed 2022-08-15 | -$10.87M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$2.84M 10-Q · filed 2022-05-16 | -$5.46M derived: sum of 2 quarters · filed 2022-05-16 | -$7.67M derived: sum of 3 quarters · filed 2022-05-16 | -$8.65M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$4.82M derived: sum of 2 quarters · filed 2022-03-28 | -$5.81M derived: sum of 3 quarters · filed 2022-03-28 | -$7.63M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$3.19M derived: sum of 2 quarters · filed 2021-11-15 | -$5.02M 10-Q · filed 2021-11-15 | -$6.77M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | -$985.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$2.81M 10-Q · filed 2021-08-12 | -$4.56M derived: sum of 3 quarters · filed 2021-08-12 | -$6.29M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$1.83M 10-Q · filed 2021-05-17 | -$3.58M derived: sum of 2 quarters · filed 2021-05-17 | -$5.30M derived: sum of 3 quarters · filed 2021-05-17 | -$6.44M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | -$3.48M derived: sum of 2 quarters · filed 2021-03-22 | -$4.62M derived: sum of 3 quarters · filed 2021-03-22 | -$6.34M 10-K · filed 2021-03-22 | |
| 2019-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$2.86M derived: sum of 2 quarters · filed 2020-11-13 | -$4.59M 10-Q · filed 2020-11-13 | -$5.69M derived: sum of 4 quarters · filed 2020-11-13 | |
| 2019-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$2.86M 10-Q · filed 2020-08-13 | -$3.97M derived: sum of 3 quarters · filed 2020-08-13 | -$4.96M derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | -$1.72M 10-Q · filed 2020-05-14 | -$2.83M derived: sum of 2 quarters · filed 2020-05-14 | -$3.82M derived: sum of 3 quarters · filed 2020-05-14 | -$4.01M derived: sum of 4 quarters · filed 2020-05-14 | |
| 2018-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | -$2.10M derived: sum of 2 quarters · filed 2020-03-20 | -$2.28M derived: sum of 3 quarters · filed 2020-03-20 | -$2.50M 10-K · filed 2020-03-20 | |
| 2018-09-30 | -$991.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$1.18M derived: sum of 2 quarters · filed 2019-11-14 | -$1.39M 10-Q · filed 2019-11-14 | -$1.52M derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-06-30 | -$188.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$403.22K 10-Q · filed 2019-08-13 | -$525.32K derived: sum of 3 quarters · filed 2019-08-13 | -$662.11K derived: sum of 4 quarters · filed 2019-08-13 | |
| 2018-03-31 | -$214.28K 10-Q · filed 2019-05-13 | -$336.38K derived: sum of 2 quarters · filed 2019-05-13 | -$473.17K derived: sum of 3 quarters · filed 2019-05-13 | ||
| 2017-12-31 | -$122.10K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | -$258.89K derived: sum of 2 quarters · filed 2019-02-19 | -$494.86K 10-K · filed 2019-02-19 | ||
| 2017-09-30 | -$136.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$372.76K 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | -$235.98K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |